A5086652821- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Peripheral Neuropathies and Disorders
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders Research
- Inflammasome and immune disorders
- Immune Cell Function and Interaction
- Kawasaki Disease and Coronary Complications
- Monoclonal and Polyclonal Antibodies Research
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Autophagy in Disease and Therapy
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Parvovirus B19 Infection Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
University of Southampton
1997-2025
University Hospital Southampton NHS Foundation Trust
2015-2024
Southampton General Hospital
2008-2020
Royal Hospital for Sick Children
2009
Royal Hospital for Children
2009
University of Birmingham
2009
Heartlands Hospital
2009
Hampton University
2006
Royal South Hants Hospital
2001
The Royal Free Hospital
1991
To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelodysplastic syndrome by comparing induction options the number of consolidation courses whether should include transplantation.We randomly assigned 1,658 than age 60 years to receive mitoxantrone/cytarabine/etoposide versus cytarabine/daunorubicin/etoposide subsequently 1,193 daunorubicin/cytarabine/thioguanine (DAT) where cytarabine dose was standard (S-DAT) double (H-DAT). Patients in this...
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations JAK2, CALR or MPL, but the contribution of inherited factors poorly characterized. Using a three-stage genome-wide association study 3,437 MPN cases and 10,083 controls, we identify two SNPs with significance JAK2(V617F)-negative MPN: rs12339666 (JAK2; meta-analysis P=1.27 × 10(-10)) rs2201862 (MECOM; P=1.96 10(-9)). Two additional SNPs, rs2736100 (TERT) rs9376092 (HBS1L/MYB), achieve when including...
The guideline group was selected to be representative of UK-based medical experts with an interest in myeloproliferative neoplasms and eosinophilia. PubMed EMBASE were searched systematically for publications English until August 2015 using the key words eosinophilia, hypereosinophilia, eosinophilic leukaemia HES. writing produced draft guideline, which subsequently revised by consensus members General Haematology Haemato-oncology Task Forces British Committee Standards (BCSH). then reviewed...
Summary The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative UK ‐based medical experts, together with a contribution from single expert USA . MEDLINE EMBASE were searched systematically for publications in E nglish 1966 until A ugust 2011 using variety key words. writing produced draft guideline, which subsequently revised by consensus members General Haematology Haemato‐oncology Task Forces British Committee Standards ( BCSH ). then...
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, 27/1715 (1.6%) cases referred investigation eosinophilia. Of 27 mutated cases, working diagnosis hypereosinophilic syndrome (HES; n = 7) or myeloid neoplasm with (n 20) had been made prior to detection N642H. Myeloid panel analysis median 2 additional genes (range 0–4) 4...
The primary objective of this study was to determine the complete remission (CR) rate achieved with FLAG (fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor) regimen in patients relapsed or refractory acute myeloid leukaemia (AML) de novo anaemia excess blasts transformation (RAEB‐t). Secondary objectives were evaluate survival toxicity. Induction treatment consisted between one two courses FLAG. Patients achieving CR received consolidation treatment. Eighty‐three 89...
Significance Bone marrow failure (BMF) is an inherited life-threatening condition characterized by defective hematopoiesis, developmental abnormalities, and predisposition to cancer. BMF caused ERCC6L2 mutations considered be a genome instability syndrome, because DNA repair compromised in patient cells. In this study, we report cases with biallelic disease-causing variants provide evidence from patients’ cells that transcription deficiency can explain the instability. Specifically,...
The myeloproliferative neoplasms (MPN) including polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but current symptom assessment tools have not been validated compared the general population. MPN-symptom form (MPN-SAF), reliable clinical tool assess MPN burden, was administered patients (n = 106) and, for first time, population controls 124) as part of...
Abstract Purpose: To determine the origin and relationship of rare IgG+ variant chronic lymphocytic leukemia (CLL) to two common IgM+IgD+ subsets that are distinguished by expression unmutated or mutated VH genes, with former having a worse prognosis. Experimental Design: CLL cells were characterized using phenotypic, functional, immunogenetic analyses. Results: was phenotypically similar (M-CLL) variably expressed CD38 (4 14). ZAP-70, tyrosine kinase preferentially in CLL, found only 2 14...
Despite the identification of acquired genetic mutations associated with Myeloproliferative Neoplasms (MPNs) there is a paucity information relating to modifiable risk factors that may lead these mutations. The MOSAICC Study was an exploratory case-control study polycythemia vera (PV), essential thrombocythemia (ET), and Myelofibrosis (MF). MPN patients population controls (identified by General Practitioners) non-blood relative/friend were recruited from 2 large UK centers. Participants...
Summary Administration of interleukin 2 (IL2) to patients with minimal residual malignant disease following myelo‐ablative chemo‐radiotherapy may augment immune reconstitution and reduce the risk relapse by increasing cytotoxic effector function cytokine dependent killing directed at cells. The ability IL2 generated activated killer cells inhibit haemopoietic progenitor release gamma‐interferon (γIFN) tumour necrosis factor (TNF) may, however, retard recovery, as both TNF γIFN normal...